Drug intelligence / Profile preview

LM-108 + sintilimab

Development stage: Unknown
Lead developer: LaNova Medicines
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

LM-108 + sintilimab is a combination therapy consisting of LM-108, an Fc-optimized anti-CCR8 monoclonal antibody, and sintilimab, an anti-PD-1 antibody. LM-108 selectively depletes tumor-infiltrating regulatory T cells (Tregs) by targeting CCR8, which is specifically upregulated in these cells across multiple cancer types. This depletion enhances anti-tumor immune responses. When combined with sintilimab, which blocks the PD-1 immune checkpoint pathway, the dual immunomodulatory approach aims to overcome resistance associated with immune checkpoint inhibitors alone.

Targets

CCR8PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on LM-108 + sintilimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LM-108 + sintilimab.

Explore the full profile